The information gathered so far demonstrated the ability of inflammatory mediators, such as pro-inflammatory cytokines (IL-1β, TNF-α, IL-6, and IL-17), CCL2, and NGF, to interact with receptors in joint nociceptors, inducing their activation and sensitization in OA and RA. This evidence concerns the gene CCL2 and rheumatoid arthritis.